Sarcoidosis is a multisystem disease characterized by the presence of non-caseating granulomas in affected organs.
Introduction
Sarcoidosis is an inflammatory disorder of unknown etiology categorized by the presence of non-caseating granulomas, which can involve multiple organs of the body, 1 in the absence of infections, other autoimmune diseases, and exposure to foreign agents. It has been estimated that the worldwide prevalence of sarcoidosis is 2-60 per 100,000 people. 2 Sarcoidosis affects all ethnicities with higher prevalence rates described in patients of Scandinavian descent. 2 In contrast, sarcoidosis has been only rarely reported in patients of Chinese and Taiwanese origin. 3, 4 In the USA, African Americans have been reported to have a three times higher age-adjusted incidence of the disease. 1, 5 Sarcoidosis affects females more often than males across all ages and ethnicities, 6 with an age peak of 20-40 years. 6 A second age peak (.50 years) has also been described. 6 The hallmark of sarcoidosis is the formation of epithelioid granulomas that are typically non-caseating, in the absence of tuberculosis, fungal infection, malignancy, or other causes of granulomatous reactions. 7 The pulmonary system is the most common site of involvement, and is affected in about 90% of cases. 6 Extra-thoracic sarcoidosis occurs in 40-50% of patients. 8 Sites affected include peripheral lymph nodes (30%), the hepatic system, the spleen, stomach, small bowel, bone, and skin. Involvement of the solid organs can present as organ enlargement. Dermatological sarcoidosis may present as erythema nodosum or lupus pernio. Myopathy, uveitis, granulomatous meningitis, facial nerve palsy, cardiomyopathy, and parotid enlargement have been reported less commonly.
There are two classic syndromes described for sarcoidosis. The first is Löfgren syndrome, which is characterized by hilar lymphadenopathy, erythema nodosum, arthritis and fever. 6 The second is Heerfordton syndrome, which is characterized by uveitis, swelling of the parotid gland, fever, and facial palsy. 9 The pathogenesis of sarcoidosis is still not completely understood, but it is thought to be multifactorial, involving the interplay of immunological, genetic, and environmental factors. 1, 6 It has been theorized that an environmental trigger initiates a specific immune reaction in a genetically predisposed individual. The immunological response in sarcoidosis includes T helper 1 (Th1) cells triggered by an antigen, leading to cytokine production, mainly tumor necrosis factor alpha 10 which in turn, leads to macrophage aggregation with subsequent granuloma formation. 11 Certain histocompatibility antigens have been associated with sarcoidosis such as human leukocyte antigen-A1 (HLA-A1), B8, DRB1, DQB1, and DRB3. 12 This suggests a genetic susceptibility and familial clustering of the disease. Some of the possible postulated triggers of environmental antigens include reactive oxygen species, and viruses (herpes simplex virus, cytomegalovirus, retroviruses) and bacteria (Borrelia burgdorferi, mycobacteria).
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Epidemiology of hepatic sarcoidosis
In biopsy and autopsy studies of patients with systemic sarcoidosis, liver involvement was found in about 50-80%, 17 whereas only 10-30% of patients presented with abnormal liver enzymes during laboratory testing. 2, 18 The majority of patients with hepatic sarcoidosis are asymptomatic, despite the presence of granulomas on biopsy, abnormal liver enzymes, or radiological evidence of disease.
14 It has been reported that the percentage of patients with clinically significant disease is less than 20%. 19 Risk factors associated with hepatic sarcoidosis include African American ethnicity, prior exposure to pegylated interferon, and the presence of splenomegaly. 13, 14, 20 Reports on the differences in prevalence based on gender have been contradictory. In studies containing hundreds of patients, one study reported liver disease to be more common in women, 21 whereas the other showed the opposite. 22 
Spectrum of hepatic sarcoidosis
There is a spectrum of clinical presentations of liver involvement in sarcoidosis. Of the more than 50% of patients who have hepatic granulomas on liver biopsy, only 10-30% have elevated serum liver enzymes. 2, 18 About 20% of patients have palpable hepatomegaly or splenomegaly. Radiological examination (ultrasound or computed tomography) is accurate in the detection of organomegaly, demonstrating this feature in about 40% of cases. 13, 17 However, even in cases of elevated serum liver enzymes or radiological abnormalities, evidence of organ dysfunction is rare.
Some clinical symptoms and signs suggest liver involvement, and may warrant a liver biopsy. Systemic symptoms such as fatigue, fever, and arthralgias are non-specific, but are present in the majority of patients with active liver sarcoidosis. 23, 24 More specific symptoms include jaundice and pruritus, mostly from chronic cholestasis. 25, 26 Right upper quadrant abdominal pain, in theory, results from stretching of the Glisson's capsule by hepatomegaly as a consequence of the increasing intrahepatic volume occupied by the developing hepatic granulomas. Abdominal pain has been reported to occur in 15% of patients with sarcoidosis, and jaundice in less than 5%. 19 Long-standing disease has been reported to result in portal hypertension in 3-18% of patients. 16 This may be due initially to compression of portal venules by granulomas, and can result in variceal bleeding. A small proportion (6-8%) of patients can develop portal hypertension because of progression to cirrhosis. Indeed, some patients can develop endstage liver disease and require liver transplantation. [26] [27] [28] These account for about 0.012% of the total number of liver transplantation cases in the USA. Unfortunately, they often have a worse prognosis than patients with other cholestastic liver diseases such as primary biliary cirrhosis and primary sclerosingcholangitis. 29 Some case reports have linked sarcoidosis with an increased risk of developing Budd-Chiari 30 syndrome, hepatopulmonary syndrome, 28 hepatocellular carcinoma, 31, 32 and biliary sarcoid mimicking cholangiocarcinoma. Table 1 lists postulated mechanisms of liver injury in hepatic sarcoidosis. Table 2 summarizes the clinical spectrum of the disease.
Investigations
Elevations of alkaline phosphatase and/or gamma glutamyltranspeptidase have been correlated with cholestasis and liver involvement. 25, 34 Alkaline phosphatase of hepatobiliary origin can be elevated 5-10 times the upper limit of normal. Aminotransferase elevations are usually mild and less frequent compared with elevations in alkaline phosphatase. 19 The severity of liver test abnormalities was shown to be associated with the extent of granulomatous inflammation. 33 Hyperglobulinema may be seen. Measurement of the serum angiotensin converting enzyme (ACE) levels can be useful; they have been reported to be elevated in about 60% of patients with active sarcoidosis. [35] [36] [37] However, the test lacks sensitivity and specificity, with low positive and negative predictive values (84 and 74%, respectively). 38 Normal levels can be seen in chronic forms and in patients who have been on corticosteroids. Therefore, a normal ACE level does not rule out sarcoidosis, but an elevated level may help distinguish sarcoidosis from other granulomatous disease. Elevated ACE levels can also be present in patients with inflammatory bowel disease. 36 Radiological studies 39 such as ultrasonography, 40 computed tomography (CT) 41 or magnetic resonance imaging (MRI) 42, 43 may show hepatomegaly or multiple hypointense or hypoattenuated liver nodules. The occurrence of such multiple nodules can be confused with liver metastasis or other granulomatous diseases. The presence of concomitant splenic granulomas may help point towards a diagnosis of sarcoidosis. Liver biopsy should be considered if the diagnosis is uncertain and treatment is considered. Some authors recommend obtaining a liver biopsy if aminotransferase levels are elevated at least two-fold above the upper limit of normal. Histopathological examination is the definitive diagnostic tool. In sarcoidosis, granulomas are usually abundant and well-formed in the periportal and the portal regions. Typically, the granulomas are non-caseating and epithelioid (Fig. 1) . There is scant lymphocytic inflammatory infiltration. Occasionally, fibrinoid necrosis, prominent fibrosis, and multinucleated giant cells can be seen. Staining for acid-fast mycobacteria, and for fungi should be negative. Progression of the disease can result in micronodular cirrhosis. 27 
Differential diagnosis
Hepatic sarcoidosis needs to be differentiated from other (autoimmune) liver diseases, especially primary biliary cirrhosis and primary sclerosing cholangitis 44, 45 (Table 3 ). The differential diagnosis of granulomatous liver disease can be separated into four main categories based on the type of granulomas present: 7 epithelioid, foreign body, lipogranulomatous, and lymphohistiocytic. Sarcoid epithelioid granulomas are characterized by macrophages that aggregate to form giant cells surrounded by fibrin rings. Table 4 includes some of these etiologies, and their differentiating characteristics. In the setting of post-transplant granulomas, it is important to remember that the treatment itself can lead to granulomas from drug reaction, and predispose patients to develop opportunistic infections that can cause liver granulomas. 7, 46, 47 In cases of sarcoidosis co-existing with hepatitis C, granulomas may be due to hepatitis C, or may have been induced by prior exposure to interferon therapy for hepatitis C. 48 
Management
When evaluating patients with hepatic sarcoidosis for treatment, consultation with other specialists involved in the patient's care is recommended to ensure that other organ systems that may be involved with sarcoidosis such as the pulmonary system, central nervous system and/or ocular systems are treated adequately. 49 
Observation without medical management
Observation alone is indicated for patients with asymptomatic liver disease or mild elevations of serum liver enzymes, and normal synthetic liver function without evidence of cholestasis. 17, 19, 49 Hepatomegaly alone noted on physical examination and/or radiographic investigation in the absence of symptoms does not qualify as an indication for treatment. It has been noted that in some asymptomatic patients, abnormal serum liver tests can resolve spontaneously or remain stable for many years.
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Medical treatment
For patients who have symptoms of liver involvement, and have biochemical evidence of cholestasis or who are at high risk for developing hepatic complications, pharmacological therapy should be considered. 17, 19, 49 The first line agents that have been studied include corticosteroids and ursodeoxycholic acid.
Steroids
It has been shown that corticosteroids can decrease the number of hepatic granulomas by suppression of the inflammatory response, 50 and reduce liver size 25 which may be helpful for patients with persistent abdominal pain due to hepatomegaly. In addition, steroids are recommended for patients with constitutional symptoms such as fever, fatigue, pruritus, and weight loss. Low-dose prednisone (10-20 mg/ daily) may be sufficient for those with mild symptoms, while a higher dose of prednisone (20-40 mg/daily) is warranted for Liver failure requiring liver transplantation 0.012% of all liver transplants in the USA those with severe symptoms. 17, 51 Prednisone can also be considered for patients with significant adenopathy in the porta hepatis.
Treatment duration should be determined by clinical and laboratory response. Some authors recommend 12 months of therapy before tapering the dose. 52 Relapsing symptoms may require long-term therapy or steroid-sparing agents. Side effects of long-term steroid use (including ostopenia, bone fractures, avascular hip necrosis, hyperglycemia, cataracts, and hypertension) should be considered. 52 No studies have reported on the use of oral budesonide (a systemic steroid eliminated on first pass through the liver) in the treatment of hepatic sarcoidosis.
The benefit of steroids in patients at the extremes of the clinical spectrum (that is, asymptomatic individuals or patients with cirrhosis and portal hypertension) is questionable. Steroids can help in the normalization of these laboratory abnormalities in asymptomatic patients with elevated aminotransferases. 14, 34 However, it is important to consider that serum liver tests can normalize 25, 34 Because there is a lack of long-term studies, it is unclear if steroids prevent liver damage or halt the progression of the disease. In patients with progressive disease (significant fibrosis, chronic cholestasis, and portal hypertension), steroid treatment has not been shown to have beneficial effects. 16 
Ursodeoxycholic acid
Ursodeoxycholic acid decreases biliary secretion of cholic and chenodeoxycholic acid, and inhibits the intestinal absorption of bile salt. It also helps to modulate the immune response by decreasing HLA class I and class II antigens on the cell membranes of the hepatic and bile duct epithelial cells, respectively. 53 Recent studies have shown a beneficial effect of this agent in the treatment of hepatic sarcoidosis, especially when patients with cholestasis are symptomatic with pruritus. 49 It has the potential effect of delaying the progression of the disease. Given its relative safety compared to steroids, some authors recommend starting with ursodeoxycholic acid before prednisone. In a recent retrospective study of 17 patients comparing placebo vs. prednisone vs. ursodeoxycholic acid, 54 ursodeoxycholic acid was found to be superior in improving aminotransferase levels, pruritus, and fatigue. 54 The usual dose is 13-15 mg/kg orally per day. 55 
Second-line and third-line agents
These agents may be useful for patients for whom prednisone fails or patients who are deemed to be steroid dependent. Azathioprine has been reported to normalize aminotransferases, but can also cause acute hepatitis. 49 Methotrexate, glutathione, chlorambucil, cyclosporine, cyclophosphamide, thalidomide, pentoxifylline, and infliximab 56, 57 have been reported to be beneficial. However, there is inadequate evidence to support the use of these agents. 49 
Treatment of advanced liver disease
Portal hypertension and decompensated cirrhosis should be managed by standard measures. Steroids may not be beneficial, and liver transplantation may be required. Reported rates of graft and patient survival for hepatic sarcoidosis are 78% at 1 year, 66-67% at 3 years, and 60-61% at 5 years. 29 Recurrence of disease in the graft has been reported. 58 
Prognosis
The mortality rate of sarcoidosis is about 1-5%. 59, 60 Death usually occurs from severe pulmonary, cardiac, and central nervous system disease rather than hepatic involvement. These survival rates are comparable to other causes of transplantation, except for PBC and PSC. 29, 61, 62 Conclusions Hepatic sarcoidosis is a granulomatous disease of unknown etiology. Around 70% of patients have epithelioid non-caseating granulomas on liver biopsy; 20-40% of patients have hepatomegaly or elevated liver enzymes. Most of the cases with liver involvement are asymptomatic and do not require treatment. Pain in the right upper quadrant of the abdomen, fatigue, pruritus, and jaundice are the most commonly associated symptoms. For symptomatic patients, prednisone and/or ursodeoxcholic acid may be considered. Those patients who do not respond to steroids and/or ursodeoxcholic acid may require other immunosuppressive agents. Portal hypertension and cirrhosis are possible complications from long-standing hepatic sarcoidosis. Patients may require liver transplantation, but disease recurrence in the graft has been reported, and survival rates tend to be lower than those for patients transplanted for other diseases. 
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